A peptide nucleic acid-based pretargeting approach using 161Tb for radionuclide therapy in a murine tumor model

Wenli Li; Xin Xiang; Lili Guan; Yì Wáng; Yuyue Feng; Xia Zhu; Wenbo Li; Jia Li; Hua Pang; Zi Wang

doi:10.1186/s13550-026-01382-3

January 30, 2026EJNMMI ResearchOpen Access

A peptide nucleic acid-based pretargeting approach using 161Tb for radionuclide therapy in a murine tumor model

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the effectiveness of a peptide nucleic acid-based pretargeting approach using 161Tb for radionuclide therapy in tumor models.
Utilized a murine tumor model for testing the therapy
Applied a peptide nucleic acid-based pretargeting strategy
Compared results with conventional radionuclide therapy
Reduced systemic radiation exposure compared to non-pretargeted therapy
Significantly decreased hematotoxicity
Suppressed tumor growth in tumor-bearing mice

Implication

Radionuclide therapy reduces radiation exposure and tumor growth in tumor-bearing mice, indicating an effective treatment strategy.

Abstract

Compared to conventional non-pretargeted radionuclide therapy, PNA-based pretargeted ¹⁶¹Tb radionuclide therapy reduced systemic radiation exposure, significantly decreased hematotoxicity, and suppressed tumor growth in tumor-bearing mice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6980fe7cc1c9540dea810916 https://doi.org/10.1186/s13550-026-01382-3

View Full Paper

Ask AI

Bookmark

Share

A peptide nucleic acid-based pretargeting approach using 161Tb for radionuclide therapy in a murine tumor model

Key Points

Implication

Abstract

Discussion

Cite This Study

A peptide nucleic acid-based pretargeting approach using 161Tb for radionuclide therapy in a murine tumor model

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading